{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:26:12Z","timestamp":1786739172982,"version":"build-2736575974"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Aripiprazole, a partial D2 receptor agonist, is proposed to enhance prefrontal cortex (PFC) dopamine function, improving working memory and GABA transmission, which supports social functioning. Long-acting injectable (LAI) antipsychotics are known to improve patient adherence, leading to enhanced long-term effects on behavioral outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate whether aripiprazole LAI treatment improves general functioning, quality of life, and reduces hospitalizations in psychotic patients, both in community settings and within incarcerated populations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, settings, and participants<\/jats:title><jats:p>The study included 55 patients, with 34 from the community and 21 incarcerated at a prison in Southeastern Greece (Neapolis). The World Health Organization Quality of Life Brief Version (WHOQOL-BREF) and the Clinical Global Impression-Severity (CGI-S) scale were used to assess outcomes. Comparisons were made between pre-treatment and post-treatment periods, with a minimum follow-up of six months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>\u2022 Demographics: Community patients (70.6% male) included 44.1% with paranoid schizophrenia. Incarcerated patients (all male) had an F29.0 diagnosis, with 57.1% exhibiting Cluster B personality disorder and all reporting psychoactive substance use.<\/jats:p><jats:p>\u2022 Hospitalizations: Community patients\u2019 hospitalizations decreased from 1.4 to 0.1 over six months (p=0.001). Incarcerated patients\u2019 hospitalizations dropped from 0.6 to 0.0 (p=0.066), with no significant intergroup difference (p=0.150).<\/jats:p><jats:p>\u2022 CGI-S: Community patients\u2019 scores improved from 6.0 to 3.9 (p&amp;lt;0.001). Incarcerated patients\u2019 scores improved from 5.3 to 3.2 (p&amp;lt;0.001), with no significant difference between groups (p=0.814).<\/jats:p><jats:p>\u2022 Quality of Life: Community patients\u2019 scores rose from 0.5 to 3.0 (p&amp;lt;0.001), while incarcerated patients\u2019 scores also increased significantly (p&amp;lt;0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study of 34 community and 21 incarcerated patients revealed significant demographic and medical history differences. Both groups experienced reduced hospitalizations and improvements in CGI-S scores and quality of life following aripiprazole LAI administration. Community patients showed a greater reduction in hospitalizations, while clinical and quality-of-life improvements were comparable across groups.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2025.1499400","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T11:06:16Z","timestamp":1754651176000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Better treatment outcomes with aripiprazole long-acting injection in community and incarcerated patients with serious mental illness"],"prefix":"10.3389","volume":"16","author":[{"given":"Erasmia I.","family":"Koiliari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Mouzas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Alevizopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Lesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil L.","family":"Pasparakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.2147\/NDT.S88117","article-title":"Aripiprazole: from pharmacological profile to clinical use","volume":"11","author":"Di Sciascio","year":"2015","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B2","volume-title":"ABILIFY (aripiprazole) tablets, ABILIFY DISCMELT (aripiprazole) orally disintegrating tablets, ABILIFY (aripiprazole) oral solution, ABILIFY (aripiprazole) injection for intramuscular use only","year":"2014"},{"key":"B3","volume-title":"Abilify 7.5 mg\/ml solution for injection (intramuscular) \u2013 summary of product characteristics (SmPC)","year":""},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(04)90066-5","article-title":"Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability","volume":"26","author":"DeLeon","year":"2004","journal-title":"Clin Ther"},{"key":"B5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0301-0082(03)00087-X","article-title":"The neurobiology and control of anxious states","volume":"70","author":"Millan","year":"2003","journal-title":"Prog Neurobiol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-016-4234-9","article-title":"An investigation into aripiprazole\u2019s partial D2 agonist effects within the dorsolateral prefrontal cortex during working memory in healthy volunteers","volume":"233","author":"Murphy","year":"2016","journal-title":"Psychopharmacol (Berl)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4306\/pi.2013.10.1.75","article-title":"Is the GABA system related to the social competence improvement effect of aripiprazole? An (18)F-fluoroflumazenil PET study","volume":"10","author":"Lee","year":"2013","journal-title":"Psychiatry Investig"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40800-016-0027-7","article-title":"Dosing recommendations of aripiprazole depot with strong cytochrome P450 3A4 inhibitors: A relapse risk","volume":"3","author":"Hahn","year":"2016","journal-title":"Drug Saf Case Rep"},{"key":"B9","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jad.2024.07.011","article-title":"Synthesising 30 years of clinical experience and scientific insight on affective temperaments in psychiatric disorders: State of the art","volume":"362","author":"Favaretto","year":"2024","journal-title":"J Affect Disord"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01670-3","article-title":"Novel agents for the pharmacological treatment of alcohol use disorder","volume":"82","author":"Burnette","year":"2022","journal-title":"Drugs"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.808002","article-title":"Long-acting injectable antipsychotic treatment in schizophrenia and co- occurring substance use disorders: A systematic review","volume":"12","author":"Coles","year":"2021","journal-title":"Front Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40801-020-00178-8","article-title":"Once-monthly long-acting injectable aripiprazole for the treatment of patients with schizophrenia and co-occurring substance use disorders: A multicentre, observational study","volume":"7","author":"Szerman","year":"2020","journal-title":"Drugs Real World Outcomes"},{"key":"B13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13561-018-0215-5","article-title":"Hospitalization rates and resource utilization of schizophrenic patients switched from oral antipsychotics to aripiprazole-depot in Germany","volume":"8","author":"Potempa","year":"2018","journal-title":"Health Econ Rev"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.3390\/brainsci13111577","article-title":"A systematic review on the effectiveness of antipsychotic drugs on the quality of life of patients with schizophrenia","volume":"13","author":"Sampogna","year":"2023","journal-title":"Brain Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/agl037","article-title":"Effects of aripiprazole on alcohol intake in an animal model of high-alcohol drinking","volume":"41","author":"Ingman","year":"2006","journal-title":"Alcohol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.alcohol.2007.11.004","article-title":"The antipsychotic aripiprazole antagonizes the ethanol- and amphetamine- induced locomotor stimulation in mice","volume":"42","author":"Jerlhag","year":"2008","journal-title":"Alcohol"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1499400\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T11:06:17Z","timestamp":1754651177000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1499400\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":16,"alternative-id":["10.3389\/fpsyt.2025.1499400"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2025.1499400","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,8]]},"article-number":"1499400"}}